Tehrani; Lida

Patent Applications and Registrations

Patent applications and USPTO patent grants for Tehrani; Lida.The latest application filed is for "cereblon binding compounds, compositions thereof, and methods of treatment therewith".

Company Profile

5.13.17

Tehrani; Lida - San Diego CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Grant 11,292,796 - Elsner , et al. April 5, 2	2022-04-05
Cereblon Binding Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20220002273 - Alexander; Matthew D. ; et al.	2022-01-06
Cereblon Binding Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20210403454 - Alexander; Matthew D. ; et al.	2021-12-30
Cereblon Binding Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20210403453 - Alexander; Matthew D. ; et al.	2021-12-30
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20200262840 - ELSNER; Jan ; et al.	2020-08-20
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Grant 10,683,298 - Elsner , et al.	2020-06-16
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20190077806 - ELSNER; Jan ; et al.	2019-03-14
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Grant 10,167,290 - Elsner , et al. J	2019-01-01
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20170342080 - ELSNER; Jan ; et al.	2017-11-30
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith Grant 9,795,607 - Calabrese , et al. October 24, 2	2017-10-24
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Grant 9,771,371 - Elsner , et al. September 26, 2	2017-09-26
Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20160324861 - Calabrese; Andrew Antony ; et al.	2016-11-10
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith Grant 9,428,509 - Calabrese , et al. August 30, 2	2016-08-30
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith Grant 9,346,812 - Calabrese , et al. May 24, 2	2016-05-24
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20160024101 - ELSNER; Jan ; et al.	2016-01-28
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20150051397 - Perrin-Ninkovic; Sophie ; et al.	2015-02-19
Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20140200207 - Calabrese; Andrew Antony ; et al.	2014-07-17
Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, And Methods Of Treatment Therewith App 20140200206 - Calabrese; Andrew Antony ; et al.	2014-07-17
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20130289271 - Perrin-Ninkovic; Sophie ; et al.	2013-10-31
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway Grant 8,507,492 - Perrin-Ninkovic , et al. August 13, 2	2013-08-13
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway Grant 8,492,381 - Perrin-Ninkovic , et al. July 23, 2	2013-07-23
Aminotriazolopyridines, Compositions Thereof, And Methods Of Treatment Therewith App 20130005707 - Bahmanyar; Sogole ; et al.	2013-01-03
Aminotriazolopyridines, compositions thereof, and methods of treatment therewith Grant 8,299,056 - Bahmanyar , et al. October 30, 2	2012-10-30
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20120071658 - Perrin-Ninkovic; Sophie ; et al.	2012-03-22
PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20120059164 - Perrin-Ninkovic; Sophie ; et al.	2012-03-08
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway Grant 8,110,578 - Perrin-Ninkovic , et al. February 7, 2	2012-02-07
mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY App 20100216781 - Perrin-Ninkovic; Sophie ; et al.	2010-08-26
Aminotriazolopyridines, Compositions Thereof, And Methods Of Treatment Therewith App 20100093698 - Bahmanyar; Sogole ; et al.	2010-04-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.